Bedrosian Camille L 4
4 · Amylyx Pharmaceuticals, Inc. · Filed Mar 9, 2026
Research Summary
AI-generated summary of this filing
Amylyx (AMLX) CMO Camille Bedrosian Receives Award
What Happened
Camille L. Bedrosian, Chief Medical Officer of Amylyx Pharmaceuticals (AMLX), received equity awards on March 5, 2026 totaling 239,975 shares: 95,990 shares reported as an RSU award and 143,985 shares reported as a derivative award. Both awards were reported at an acquisition price of $0.00 (i.e., granted, not purchased). These are compensatory grants tied to continued service and vesting schedules rather than open-market purchases or sales.
Key Details
- Transaction date: March 5, 2026; Form 4 filed March 9, 2026 (timely under Form 4 rules).
- Awards: 95,990 RSUs (grant) + 143,985 derivative shares = 239,975 total shares; reported price $0.00.
- Vesting (from filing footnotes):
- RSUs (95,990): vest in 4 equal annual installments; first vesting on March 1, 2027, subject to continued service.
- Derivative award (143,985): 25% vests on March 1, 2027, remainder vests monthly over the next 36 months, subject to continued service.
- Shares owned after the transaction: not specified in the provided filing excerpt.
- No sale or cash exercise occurred — these are awards/compensation, not market transactions.
Context
- Grants at $0 typically reflect compensation (RSUs or option-type awards) and carry vesting/service conditions; they do not represent an immediate cash outlay or open-market trading signal.
- Because vesting is contingent on continued service, these awards do not provide immediate liquidity to the insider and should be viewed as part of long-term compensation.
Insider Transaction Report
Form 4
Bedrosian Camille L
Chief Medical Officer
Transactions
- Award
Common Stock
[F1]2026-03-05+95,990→ 265,285 total - Award
Stock Option (Right to Buy)
[F2]2026-03-05+143,985→ 143,985 totalExercise: $14.10Exp: 2036-03-05→ Common Stock (143,985 underlying)
Footnotes (2)
- [F1]The reported transaction involves the Reporting Person's receipt of a restricted stock unit ("RSU") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
- [F2]25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date.
Signature
/s/ Joshua B. Cohen, as Attorney in Fact|2026-03-09